Greater than 60% increase in laboratory space will strengthen R&D capabilities, facilitate acceleration toward clinical development, and increase ability to tap into Heidelberg’s world-class medical oncology environment Zurich, Switzerland (GLOBE NEWSWIRE) - VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has moved into additional laboratory space at its existing R&D site in Heidelberg, Germany, based on a...